| Silvia Saboia Martins | |
| Birth Place: | Brazil |
| Workplaces: | Columbia University Johns Hopkins University Columbia University Mailman School of Public Health |
| Alma Mater: | University of São Paulo Federal University of Paraná |
Silvia Saboia Martins is a Brazilian epidemiologist and the director of the Substance Use Epidemiology Unit of the Department of Epidemiology, Columbia University Mailman School of Public Health. Her research considers the epidemiology of substances abuse and origins of high opioid prescribing. She has won numerous awards for her mentoring, including the Irving Medical Center Mentor of the Year.
Martins earned her medical degree at the Federal University of Paraná.[1] She moved to the University of São Paulo for her psychiatry residency and doctoral studies, where she was awarded a São Paulo Research Foundation predoctoral fellowship. She was a postdoctoral fellow at Johns Hopkins University, where she was appointed to the faculty in 2005.[2] Here she studied the prevalence of gambling among young people, and found that around 15% of African-American inner-city young people had some form of problem gambling.[3]
In 2012 Martins joined Columbia University.[4] Her research focuses on the epidemiology of substance use. She has studied the impact of medical and recreational cannabis laws in the United States. Her focus extends to exploring the combined effects of opioid and cannabis policies on mitigating opioid-related harm outcomes in the country. She also studies the trends in drug overdoses in Latin America. She has analysed the implications of opioid and substance use policies specifically designed for pregnant and postpartum women who are opioid users in the U.S. She found that during 2020 overdoses played a role in one in six pregnancy-associated deaths.[5]
She has studied the typology of prescription drug monitoring programs, and how it impacts opioid and heroin overdoses. She has developed machine learning techniques to understand high opioid prescribing.
She was elected to the board of directors of the College on Problems of Drug Dependence in 2022.